Dean Stamos

Dean Stamos joined Flagship Pioneering in 2021. In his role as Science Partner, Dean leads the creation of new discovery and treatment paradigms to profoundly expand the range and reach of small molecule medicinal chemistry.

Dean has over 27 years of medicinal chemistry experience working in the areas of immunology, oncology, infectious diseases, pain, and neuroscience. His industry career started at Vertex Pharmaceuticals (Cambridge and San Diego), where he contributed to the discovery of multiple pre-clinical and clinical stage small molecules, including SPR-719/720 (licensed to Spero Therapeutics) for the treatment of Nontuberculous Mycobacterial Pulmonary Disease, and the non-opioid analgesic VX-458 (Suzetrigine) for the treatment of pain. In 2017 he joined Vividion Therapeutics as the founding head of chemistry and served on the leadership team.

As a passionate champion of chemistry, innovation, and change, he established several collaborations with world renowned academic institutions including the Scripps Research Institute, Scripps Institute for Oceanography, and Leiden University; he created the first chemical biology group at Vertex; and he spearheaded change management initiatives to unite cutting-edge science and disruptive technologies with industrial small molecule drug discovery. His pursuit of chemical innovation culminated in the creation of the Vividion Therapeutics’ chemical proteomics platform, where he served as a founding member of the leadership team and head of chemistry innovation.

Dean earned a B.S in Chemistry from Indiana University and a Ph.D. in Organic Chemistry at Harvard University in the labs of Prof. Yoshito Kishi. He is an inventor and co-author of more than 50 patents and publications.